Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Safety
Liposomal amphotericin B safe/effective for pediatric visceral leishmaniasis
October 23rd, 2005
Liposomal amphotericin B is safe and effective for the treatment of pediatric visceral leishmaniasis. In a recent report, researchers in France described "liposomal amphotericin B (AmBisome) use as first line treatment of pediatric visceral leishmaniasis" and evaluated "the incidence of the disease in southern France" from a retrospective "chart review of children referred for visceral leishmaniasis from 1996 to 2003." "Thirty-two children under 15 years of age and suffering from visceral leishmaniasis were treated with liposomal amphotericin B as first line treatment. Clinical and biological features were usual: age <5 years, no immunodeficiency,...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
